EUVIMEDEUVIMED entdecken
Übersichtsarbeit

HBV Biomarkers and Their Role in Guiding Treatment Decisions

Lung-Yi Mak, Tobias Boettler, Upkar S Gill

Seminars in Liver Disease · 01.11.2024 · 44 (04) · 474-491

DOI: 10.1055/a-2448-4157 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, erschienen am 01.11.2024. Verfasst von Lung-Yi Mak und 2 weiteren Autor:innen. Beteiligte Einrichtung: Barts Liver Centre, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom. Hauptthemen laut MEDLINE: Biomarkers, Hepatitis B, Chronic, Antiviral Agents, Hepatitis B virus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 192 Literaturangaben. Gefördert von: Medical Research Foundation, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over 300 million individuals worldwide are chronically infected with hepatitis B virus and at risk for progressive liver disease. Due to the lack of a therapy that reliably achieves viral elimination and the variability of liver disease progression, treatment decisions are guided by the degree of liver disease and viral biomarkers as the viral life-cycle is well characterized and largely conserved between individuals. In contrast, the immunological landscape is much more heterogeneous and diverse and the measurement of its components is less well standardized. Due to the lack of a universal and easily measurable set of biomarkers, clinical practice guidelines remain controversial, aiming for a balance between simplifying treatment decisions by reducing biomarker requirements and using all available biomarkers to avoid overtreatment of patients with low risk for disease progression. While approved therapies such as nucleos(t)ide analogs improve patient outcomes, the inability to achieve a complete cure highlights the need for novel therapies. Since no treatment candidate has demonstrated universal efficacy, biomarkers will remain important for treatment stratification. Here, we summarize the current knowledge on virological and immunological biomarkers with a specific focus on how they might be beneficial in guiding treatment decisions in chronic hepatitis B.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersHepatitis B, ChronicAntiviral AgentsHepatitis B virusHumansClinical Decision-MakingDNA, Viral

Substanzen

BiomarkersAntiviral AgentsDNA, Viral

Autor:innen und Institutionen

  • Barts Liver Centre, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
  • Department of Medicine, Queen Mary Hospital, School of Clinical Medicine, The Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
  • Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Förderung

  • Medical Research Foundation
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Mak, L. Y., Boettler, T., & Gill, U. S. (2024). HBV Biomarkers and Their Role in Guiding Treatment Decisions. Seminars in Liver Disease, 44(04), 474-491. https://doi.org/10.1055/a-2448-4157

Vancouver

Mak LY, Boettler T, Gill US. HBV Biomarkers and Their Role in Guiding Treatment Decisions. Seminars in Liver Disease. 2024;44(04):474-491. doi:10.1055/a-2448-4157

BibTeX
@article{Mak2024,
  author = {Mak, Lung-Yi and Boettler, Tobias and Gill, Upkar S},
  title = {HBV Biomarkers and Their Role in Guiding Treatment Decisions},
  journal = {Seminars in Liver Disease},
  year = {2024},
  volume = {44},
  number = {04},
  pages = {474--491},
  doi = {10.1055/a-2448-4157}
}
Kostenlos starten →